O'Brien Greene & Co’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$776K Hold
5,081
0.22% 63
2025
Q4
$701K Hold
5,081
0.21% 69
2025
Q3
$652K Sell
5,081
-617
-11% -$75.3K 0.2% 71
2025
Q2
$690K Hold
5,698
0.23% 67
2025
Q1
$635K Hold
5,698
0.21% 67
2024
Q4
$554K Buy
5,698
+124
+2% +$13.2K 0.18% 76
2024
Q3
$641K Sell
5,574
-124
-2% -$14.1K 0.2% 73
2024
Q2
$607K Buy
5,698
+124
+2% +$12.4K 0.19% 78
2024
Q1
$539K Hold
5,574
0.18% 82
2023
Q4
$563K Hold
5,574
0.2% 77
2023
Q3
$568K Hold
5,574
0.21% 73
2023
Q2
$563K Hold
5,574
0.2% 77
2023
Q1
$513K Hold
5,574
0.19% 79
2022
Q4
$506K Sell
5,574
-11,538
-67% -$972K 0.19% 78
2022
Q3
$1.3M Buy
17,112
+11,408
+200% +$946K 0.17% 89
2022
Q2
$483K Hold
5,704
0.18% 83
2022
Q1
$500K Hold
5,704
0.17% 87
2021
Q4
$499K Buy
5,704
+130
+2% +$10.8K 0.16% 88
2021
Q3
$456K Hold
5,574
0.17% 90
2021
Q2
$508K Hold
5,574
0.18% 84
2021
Q1
$477K Hold
5,574
0.19% 84
2020
Q4
$526K Hold
5,574
0.22% 81
2020
Q3
$485K Hold
5,574
0.23% 74
2020
Q2
$487K Hold
5,574
0.26% 73
2020
Q1
$460K Hold
5,574
0.31% 68
2019
Q4
$528K Hold
5,574
0.27% 77
2019
Q3
$484K Hold
5,574
0.26% 77
2019
Q2
$509K Sell
5,574
-647
-10% -$54.8K 0.27% 78
2019
Q1
$536K Hold
6,221
0.27% 78
2018
Q4
$478K Buy
+6,221
New +$484K 0.28% 66

Other funds holding NVS

O'Brien Greene & Co's NVS Position: Q1 2026 in Review

O'Brien Greene & Co held its Novartis (NVS) position steady in Q1 2026 at 5,081 shares worth $776K. The position accounts for 0.22% of the portfolio, ranked #63.

O'Brien Greene & Co first reported a position in NVS in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.3M in Q3 2022. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • O'Brien Greene & Co held 5,081 shares of Novartis worth $776K as of Q1 2026.
  • O'Brien Greene & Co left its Novartis share count unchanged in Q1 2026.
  • Novartis made up 0.22% of O'Brien Greene & Co's portfolio in Q1 2026, its #63 holding.
  • O'Brien Greene & Co first reported a position in Novartis in Q4 2018 and has held it in 30 quarters since.
  • O'Brien Greene & Co's Novartis position peaked at $1.3M in Q3 2022.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on O'Brien Greene & Co's 13F filing for Q1 2026, filed 6 May 2026.